Keyphrases
30-day Readmission
100%
Atrial Fibrillation
100%
Budesonide
40%
Cerner
46%
Chi-square Analysis
20%
Chronic Obstructive Pulmonary Disease
100%
Chronic Obstructive Pulmonary Disease Patient
20%
Chronic Obstructive Pulmonary Disease Treatment
20%
Clinical Decisions
20%
Combination Treatment
20%
Coronary Artery Disease
100%
Diabetic Women
28%
Digoxin
100%
Diltiazem
100%
Drug Treatment
100%
Drug Trials
20%
Drug Type
20%
EHR Data
100%
Electronic Health Record Data
100%
Electronic Health Records
33%
Fluticasone Propionate
40%
Health Facts
53%
Hormone Replacement Therapy
100%
Hospital Location
20%
Hospital Readmission
20%
Hospital Setting
20%
Hospital-associated
20%
Length of Hospital Stay
20%
Lung Disease
20%
Matched Cohort Study
100%
Medicaid Patients
20%
Mortality Rate
40%
Mortality Risk
20%
No Significant Difference
20%
Patient Demographics
20%
Patient Management
20%
Payer Type
20%
Payers
20%
Pharmacological Treatment
40%
Postmenopausal Women
100%
Premarin
28%
Propensity Score Matching
20%
Public Health Risk
20%
Quality Assessment
33%
Readmission Rates
40%
Rural Areas
20%
Salmeterol
40%
Type 2 Diabetes Mellitus (T2DM)
28%
Type 2 Diabetic
100%
Urban Hospitals
20%
Nursing and Health Professions
Adverse Outcome
10%
Atrial Fibrillation
100%
Budesonide/Formoterol
25%
Calcium Channel Blocking Agent
10%
Cerner
22%
Chi Square Test
12%
Cohort Analysis
100%
Combination Therapy
12%
Coronary Artery Disease
100%
Diabetes Mellitus
28%
Diethylstilbestrol
28%
Digoxin
100%
Diltiazem
100%
Drug Screening
12%
Drug Therapy
100%
Electronic Medical Record
14%
Ethinylestradiol
28%
Female Patient
10%
Fluticasone/Salmeterol
25%
Hormone Substitution
100%
Hospital Readmission
100%
Hospital Setting
12%
Length of Stay
22%
Lung Disease
12%
Marital Status
12%
Medicare
12%
Menopausal Syndrome
14%
Mortality Rate
50%
Non Insulin Dependent Diabetes Mellitus
28%
Nutrition Policy
12%
Obstructive Lung Disease
100%
Patient Care
25%
Premarin
28%
Prevalence
100%
Propensity Score
12%
Survival Rate
10%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Outcome
10%
Atrial Fibrillation
100%
Budesonide Plus Formoterol
40%
Calcium Channel Blocker
10%
Chronic Obstructive Lung Disease
100%
Cohort Study
100%
Combination Therapy
20%
Conjugated Estrogen
28%
Coronary Artery Disease
100%
Diabetes Mellitus
28%
Diethylstilbestrol
28%
Digoxin
100%
Diltiazem
100%
Drug Screening
20%
Ethinylestradiol
28%
Fluticasone
40%
Lung Disease
20%
Menopausal Syndrome
14%
Mortality Rate
50%
Non Insulin Dependent Diabetes Mellitus
28%
Pharmacotherapy
100%
Phase IV
20%
Prevalence
100%
Replacement Therapy
100%
Salmeterol
40%
Survival Rate
10%